NCEL NewcelX Ltd. NASDAQ · Switzerland

NewcelX (NCEL) news

Top story · Jul 31, 2026 · Company press release

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program...

Source: 6-K filed Jul 31, 2026 on SEC EDGAR

Latest NewcelX news

We have not published a story on NewcelX yet. When there is news, it will appear here.

NewcelX annual financials

Line	FY2025	FY2024
Research and development	$1.1 million	$992,000
Net income (loss)	-$8.3 million	-$7.2 million
Cash from operations	-$2.8 million	-$1.1 million
Cash and equivalents	$2.2 million	$650,000

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $2.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about NewcelX

What is the ticker symbol of NewcelX?

NewcelX Ltd. trades under the ticker NCEL on NASDAQ.

Where is NewcelX listed?

NewcelX Ltd. is listed on NASDAQ.

What is the SEC CIK of NewcelX?

The SEC Central Index Key (CIK) for NewcelX Ltd. is 1783036. Its filings are on SEC EDGAR.

How many shares does NewcelX have outstanding?

4,797,505 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-29.

Which country or territory is NewcelX listed under?

Our directory records NewcelX Ltd. under Switzerland.

What does NewcelX do?

Our directory classifies NewcelX Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of NewcelX?

The ISIN recorded for NewcelX Ltd. is CH1442297896.

Does aibio.space cover NewcelX?

aibio.space lists NewcelX Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is NewcelX incorporated?

SEC records list its state or country of incorporation as V8.

Is NewcelX profitable?

NewcelX Ltd. reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2025, and used $2.8 million of cash in operations, per its annual report to the SEC.

How much does NewcelX spend on research and development?

$1.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does NewcelX have?

$2.2 million in cash at Dec 31, 2025, per its 20-F.

Is NewcelX a smaller reporting company?

SEC records list NewcelX Ltd.'s filer category as: Non-accelerated filer<br>Emerging growth company.

Where is NewcelX headquartered?

SEC records list its business address as THE CIRCLE 6, ZURICH.

When does NewcelX's fiscal year end?

NewcelX Ltd.'s fiscal year ends on December 31, per SEC records.

Investor discussion: NewcelX

Members talk about NewcelX (NCEL). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at NewcelX, newest first. Each line links the filing it comes from.

Sep 18, 2026Financings
Reported a financing. SEC Form 6-K. Source
Jul 31, 2026Financings
Reported a financing. SEC Form 6-K. Source
Jun 15, 2026Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 6-K. Source
Apr 30, 2026Financings
Reported a financing. SEC Form 6-K. Source
Apr 1, 2026Financings
Reported a financing. SEC Form 6-K. Source
Oct 29, 2025Listings
Reported a reverse stock split. SEC Form 6-K. Source
Oct 28, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Oct 23, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Oct 10, 2025Listings
Reported a reverse stock split. SEC Form 6-K. Source
Oct 6, 2025Financings
Reported a financing. SEC Form 6-K. Source
Sep 30, 2025Listings
Reported a reverse stock split. SEC Form 6-K. Source
Aug 6, 2025Financings
Reported a financing. SEC Form 6-K. Source
Jul 18, 2025Mergers
Reported a merger or acquisition agreement. SEC Form 6-K. Source
May 1, 2025Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Mar 31, 2025Financings
Reported a financing. SEC Form 6-K. Source
Mar 10, 2025Mergers
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Dec 11, 2024Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Nov 5, 2024Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Nov 4, 2024Mergers
Reported a merger or acquisition agreement. SEC Form 6-K. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:NCEL on TradingView.

SEC filings and registration

SEC name: NewcelX Ltd.
CIK: 1783036
Industry (SIC): Pharmaceutical Preparations (2834)
US tickers: NCEL (Nasdaq)
State or country of incorporation: V8
Fiscal year ends: December 31
Filer category: Non-accelerated filer<br>Emerging growth company
Business address: THE CIRCLE 6, ZURICH
Phone: 41-41-618-80-00
Shares outstanding: 4,797,505 as of 2025-12-31 (20-F filed 2026-04-29)
Former names: NLS Pharmaceutics Ltd.

Recent filings (8-K and 6-K are the company's own announcements)

6-K filed 2026-09-18
6-K filed 2026-08-03
6-K filed 2026-07-31
6-K filed 2026-07-15
6-K filed 2026-07-08
6-K filed 2026-07-01
6-K filed 2026-06-30
6-K filed 2026-06-15

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

NewcelX Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NCEL, recorded under Switzerland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: NewcelX Ltd.
Ticker: NCEL
Listing: NASDAQ
Country or territory: Switzerland
Business scope: Biotechnology
ISIN: CH1442297896
Last quote in directory: 2026-10-21
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction